SCHEMBL249943

SCHEMBL249943

O=C(NCc1ccccc1)C1C=CCN1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.50
TSHR P16473 2/20 0.50
MC4R P32245 2/20 0.50
ALDH1A1 P00352 2/20 0.50
USP2 O75604 1/20 0.50
HSD17B10 Q99714 1/20 0.50
NPSR1 Q6W5P4 2/20 0.47
HTR1A P08908 1/20 0.44
HTR1B P28222 1/20 0.44
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
HTR2B P41595 1/20 0.44
F2 P00734 1/20 0.44
HTT P42858 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
PKM P14618 1/20 0.43
CYP2C19 P33261 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14542741 0.71 F2 (0.58) F2
SCHEMBL563687 0.71 PSEN1 (0.47) TSHRALDH1A1HSD17B10CYP3A4
SCHEMBL11043806 0.71 TSHR (0.56) HPGDTSHRMC4RALDH1A1USP2
SCHEMBL2469546 0.70 ALDH1A1 (0.86) HPGDTSHRMC4RALDH1A1USP2
SCHEMBL30239976 0.70 MC4R (0.74) HPGDTSHRMC4RALDH1A1USP2
SCHEMBL29675228 0.70 ALDH1A1 (0.86) HPGDTSHRMC4RALDH1A1USP2
SCHEMBL18546533 0.69 CFD (0.60) HPGDTSHRMC4RALDH1A1USP2
SCHEMBL15152105 0.69 TSHR (0.54) HPGDTSHRMC4RALDH1A1USP2
SCHEMBL5738027 0.68 POLB (0.41) TSHRALDH1A1HTT
SCHEMBL22462992 0.68 NPSR1 (0.81) HPGDTSHRALDH1A1USP2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
EP-1963262-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2008-09-03 EP disclosed
WO-2007069020-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 HPGD 19/4885TSHR 3341/4885MC4R 4368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.